Shot from the film “The Boss Baby: Family Business”; Credit: Dreamworks

Larry Mantle and KPCC film critics Lael Loewenstein, Wade Major and Charles Solomon review this weekend’s new movie releases on streaming and on demand platforms.

• "The Forever Purge," in wide release

• "The Boss Baby: Family Business," in wide release & on Peacock

• "Long Story Short," at Laemmle’s Glendale; & on VOD/Digital (including Vudu, FandangoNow & Google Play)

• "The Tomorrow War," on Amazon Prime Video

• "The One And Only Dick Gregory," premieres on Showtime July 4 at 9 pm PT, available on demand on Showtime following that

• "No Sudden Move," on HBO Max

• "The Ladykillers (Originally released in 1955)," at Laemmle Theaters (Royal, Town Center 5, Playhouse 7)

• "America: The Motion Picture," on Netflix

Our FilmWeek critics have been curating personal lists of their favorite TV shows and movies to binge-watch during self-quarantine. You can see recommendations from each of the critics and where you can watch them here.

Guests:

Lael Loewenstein, film critic for KPCC; she tweets @LAELLO

Wade Major, film critic for KPCC and CineGods.com

Charles Solomon, film critic for KPCC, Animation Scoop and Animation Magazine

This content is from Southern California Public Radio. View the original story at SCPR.org.

Hercules Metals Corp. (BADEF:OTCMKTS; BIG:TSXV) has announced advancements in its exploration efforts at the western Idaho Leviathan porphyry copper system. Read more about the significant shallow mineralization discoveries and new target areas that could indicate further resource potential.

Skyharbour Resources Ltd. (SYH:TSX.V; SYHBF:OTCQX; SC1P:FSE) announced it has entered into an agreement with Hatchet Uranium Corp. to acquire interest in several of its projects. One analyst says the "spotlight" is on uranium juniors as the energy transition drives a heightened demand for power sources.

Catawba County Animal Services has a DOMESTIC SH CAT ready for you to adopt! He is approximately 6 month(s) old.

Catawba County Animal Services has a DOMESTIC SH CAT ready for you to adopt! He is approximately 4 month(s) old.

Catawba County Animal Services has a DOMESTIC SH CAT ready for you to adopt! He is approximately 1.5 month(s) old.

Catawba County Animal Services has a DOMESTIC SH CAT ready for you to adopt! He is approximately 1.5 month(s) old.

Catawba County Animal Services has a DOMESTIC SH CAT ready for you to adopt! He is approximately 2 year(s) old.

Catawba County Animal Services has a DOMESTIC SH CAT ready for you to adopt! She is approximately 1.5 month(s) old.

Catawba County Animal Services has a DOMESTIC SH CAT ready for you to adopt! He is approximately 1.5 month(s) old.

Catawba County Animal Services has a DOMESTIC SH CAT ready for you to adopt! She is approximately 8 month(s) old.

Catawba County Animal Services has a DOMESTIC SH CAT ready for you to adopt! He is approximately 2 month(s) old.

Catawba County Animal Services has a DOMESTIC SH CAT ready for you to adopt! She is approximately 2 year(s) old.

Full Text:

National Science Foundation-funded engineers have developed a mathematical framework that can turn any sheet of material into any prescribed shape, inspired by the paper craft kirigami (from the Japanese, kiri, meaning to cut and kami, meaning paper). Unlike its better-known cousin origami, which uses folds to shape paper, kirigami relies on a pattern of cuts in a flat paper sheet to change its flexibility and allow it to morph into 3D shapes. Artists have long used this artform to create everything from pop-up cards to castles and dragons. This research follows previous work by the researchers that characterized how origami-based patterns could be used as building blocks to create almost any three-dimensional curved shape. Next the researchers aim to explore how to combine cuts and folds to achieve any shape with a given set of properties, thus linking origami and kirigami.

Image credit: Harvard SEAS

Source: Ed Arce 10/09/2024

H.C. Wainwright & Co. analysts Ed Arce and Thomas Yip, in a research report published on October 9, 2024, maintained a Buy rating on Unicycive Therapeutics Inc. (UNCY:NASDAQ) with a price target of US$2.50. The report follows Unicycive's announcement of the successful completion of the Phase 1 study for UNI-494 in healthy volunteers.

Arce and Yip highlighted the significance of the study results, stating, "UNI-494 showed rapid metabolism, enabling the expected release of nicorandil and its linker." They added, "Importantly, PK results collected in the study showed fast absorption of UNI-494, with rapid metabolism leading to the expected release of nicorandil and its linker."

The analysts noted the safety profile of UNI-494, commenting, "UNI-494 was generally safe and well-tolerated; headache was the most common adverse event (AE), and all AEs were mild with no serious adverse events (SAEs) or AEs leading to withdrawal in Part 1."

Regarding Unicycive's strategic plans, the analysts stated, "Management plans to request a meeting with the FDA by year-end 2024 to review these Phase 1 results and discuss the design of a potential Phase 2 study in patients with acute kidney injury (AKI)."

The report also highlighted the pending milestone for Unicycive's other product candidate, Oxylanthanum Carbonate (OLC), noting, "We await the FDA's formal acceptance of the NDA for Oxylanthanum Carbonate (OLC) for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis (we expect by November 2) with a PDUFA date assignment to further narrow OLC's potential approval timing."

H.C. Wainwright & Co.'s valuation methodology for Unicycive is based on a risk-adjusted Net Present Value (rNPV) model. The analysts explained, "We employ a rNPV valuation model to estimate the value of UNCY shares and arrive at our US$2.50 PT based on: (1) about US$2.30 per share for royalties on net sales of OLC in the U.S. and EU (85% PoS, US$149.1M global peak revenue in 2034); and (2) about US$0.25 per share for royalties on net sales of UNI-494 in the U.S. and EU for AKI (20% PoS; US$195M global peak revenue in 2036)."

They added, "In our valuation model, we employ a 14.5% discount rate, which we believe adequately reflects the overall risks of the Unicycive development pipeline. We conservatively assume zero terminal value after the end of the market exclusivity period that runs through 2037."

The analysts also outlined several risk factors, including regulatory, commercialization, market, intellectual property, and funding risks.

In conclusion, H.C. Wainwright & Co.'s maintenance of a Buy rating and US$2.50 price target reflects a positive outlook on Unicycive Therapeutics' potential in developing UNI-494 for AKI and OLC for hyperphosphatemia. The share price at the time of the report of US$0.36 represents a potential return of approximately 594% to the analysts' target price, highlighting the upside potential if the company's clinical development and regulatory plans prove successful.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
2. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for H.C. Wainwright & Co., Unicycive Therapeutics Inc., October 9, 2024

Important Disclaimers This material is confidential and intended for use by Institutional Accounts as defined in FINRA Rule 4512(c). It may also be privileged or otherwise protected by work product immunity or other legal rules. If you have received it by mistake, please let us know by e-mail reply to unsubscribe@hcwresearch.com and delete it from your system; you may not copy this message or disclose its contents to anyone. The integrity and security of this message cannot be guaranteed on the Internet.

H.C. WAINWRIGHT & CO, LLC RATING SYSTEM: H.C. Wainwright employs a three tier rating system for evaluating both the potential return and risk associated with owning common equity shares of rated firms. The expected return of any given equity is measured on a RELATIVE basis of other companies in the same sector. The price objective is calculated to estimate the potential movements in price that a given equity could reach provided certain targets are met over a defined time horizon. Price objectives are subject to external factors including industry events and market volatility.

H.C. Wainwright & Co, LLC (the “Firm”) is a member of FINRA and SIPC and a registered U.S. Broker-Dealer. I, Ed Arce and Thomas Yip , certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies. None of the research analysts or the research analyst’s household has a financial interest in the securities of Unicycive Therapeutics, Inc. (including, without limitation, any option, right, warrant, future, long or short position). As of September 30, 2024 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Unicycive Therapeutics, Inc..

Neither the research analyst nor the Firm knows or has reason to know of any other material conflict of interest at the time of publication of this research report. The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services. The Firm or its affiliates did not receive compensation from Unicycive Therapeutics, Inc. for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report. The Firm does not make a market in Unicycive Therapeutics, Inc. as of the date of this research report. The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Past performance is no guarantee of future results. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. This research report is not intended to provide tax advice or to be used to provide tax advice to any person. Electronic versions of H.C. Wainwright & Co., LLC research reports are made available to all clients simultaneously. No part of this report may be reproduced in any form without the expressed permission of H.C. Wainwright & Co., LLC. Additional information available upon request. H.C. Wainwright & Co., LLC does not provide individually tailored investment advice in research reports. This research report is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this research report. H.C. Wainwright & Co., LLC’s and its affiliates’ salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed in this research report. H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data on the company, industry or security discussed in the report. All opinions and estimates included in this report constitute the analyst’s judgment as of the date of this report and are subject to change without notice. Securities and other financial instruments discussed in this research report: may lose value; are not insured by the Federal Deposit Insurance Corporation; and are subject to investment risks, including possible loss of the principal amount invested.

( Companies Mentioned: UNCY:NASDAQ, )

Source: Dr. Ram Selvaraju 10/18/2024

H.C. Wainwright & Co. analyst Dr. Ram Selvaraju, in a research report published on October 18, 2024, reiterated a Buy rating on Anavex Life Sciences Corp. (AVXL:NASDAQ) with a price target of US$40.00. The report follows Anavex's announcement of encouraging preliminary electroencephalography (EEG) biomarker results from Part A of the ongoing Phase 2 clinical study of ANAVEX3-71 for schizophrenia treatment.

Selvaraju highlighted the significance of these results, stating, "Preliminary results demonstrated a dose-dependent effect of ANAVEX3-71 on two key EEG biomarkers in patients with schizophrenia. Treatment with ANAVEX3-71 vs. placebo resulted in improvements in 40 Hz Auditory Steady-State Response (ASSR) Inter Trial Coherence (ITC) and Resting State Alpha Power."

The analyst viewed these developments positively, noting, "These results provide evidence of CNS target engagement and potential therapeutic effects of ANAVEX3-71 in schizophrenia. The observed changes reversed known EEG and ERP biomarker abnormalities associated with schizophrenia."

Regarding Anavex's lead candidate, blarcamesine, Selvaraju stated, "Anavex remains committed to completing the Marketing Authorization Application (MAA) submission to the European Medicines Agency (EMA) under the Centralized Procedure petitioning for approval of blarcamesine for treatment of Alzheimer's disease (AD) in 4Q24."

The report also highlighted Anavex's progress with other clinical programs, including a pivotal Phase 2b/3 trial in Parkinson's disease and potential trials in Rett syndrome and Fragile X Syndrome.

Selvaraju's valuation methodology for Anavex Life Sciences is based on a discounted cash flow (DCF) approach. He explained, "We utilize a discounted cash flow (DCF)-driven methodology, which ascribes a total value of roughly US$3.25B to blarcamesine alone without ascribing value to any other pipeline assets. We employ a 50% probability of approval in Rett syndrome; 60% in Parkinson's disease dementia (PDD); and 50% in AD."

The analyst added, "Further, we apply a 12% discount rate and 1% terminal growth rate. We derive a total firm value of ~US$3.4B, which yields a 12-month price objective of US$40 per share, assuming 84.8M shares outstanding as of end-F2Q25."

Selvaraju also outlined several risk factors, including potential negative clinical data, regulatory approval challenges, and commercialization difficulties.

In conclusion, H.C. Wainwright & Co.'s maintenance of a Buy rating and US$40 price target reflects a positive outlook on Anavex Life Sciences' clinical progress and potential in developing treatments for neurological disorders. The share price at the time of the report of US$5.51 represents a potential return of approximately 626% to the analyst's target price, highlighting the significant upside potential if the company's clinical development plans prove successful.

Important Disclosures:

1. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
2. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for H.C. Wainwright & Co., Anavex Life Sciences Corp., October 18, 2024.

This material is confidential and intended for use by Institutional Accounts as defined in FINRA Rule 4512(c). It may also be privileged or otherwise protected by work product immunity or other legal rules. If you have received it by mistake, please let us know by e-mail reply to unsubscribe@hcwresearch.com and delete it from your system; you may not copy this message or disclose its contents to anyone. The integrity and security of this message cannot be guaranteed on the Internet. H.C. WAINWRIGHT & CO, LLC RATING SYSTEM: H.C. Wainwright employs a three tier rating system for evaluating both the potential return and risk associated with owning common equity shares of rated firms. The expected return of any given equity is measured on a RELATIVE basis of other companies in the same sector. The price objective is calculated to estimate the potential movements in price that a given equity could reach provided certain targets are met over a defined time horizon. Price objectives are subject to external factors including industry events and market volatility.

H.C. Wainwright & Co, LLC (the “Firm”) is a member of FINRA and SIPC and a registered U.S. Broker-Dealer. I, Raghuram Selvaraju, Ph.D. , certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies. None of the research analysts or the research analyst’s household has a financial interest in the securities of Anavex Life Sciences Corp. (including, without limitation, any option, right, warrant, future, long or short position). As of September 30, 2024 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of Anavex Life Sciences Corp.. Neither the research analyst nor the Firm knows or has reason to know of any other material conflict of interest at the time of publication of this research report.

The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services. Mr. Selvaraju, who is [the][an] author of this report, is the Chairman of and receives compensation from Relief Therapeutics Holding SA, a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent protected products in selected specialty, rare and ultra-rare disease areas on a global basis ("Relief"). You should consider Mr. Selvaraju's position with Relief when reading this research report. The firm or its affiliates received compensation from Anavex Life Sciences Corp. for non-investment banking services in the previous 12 months. The Firm or its affiliates did not receive compensation from Anavex Life Sciences Corp. for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report. The Firm does not make a market in Anavex Life Sciences Corp. as of the date of this research report. The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Past performance is no guarantee of future results. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. This research report is not intended to provide tax advice or to be used to provide tax advice to any person. Electronic versions of H.C. Wainwright & Co., LLC research reports are made available to all clients simultaneously. No part of this report may be reproduced in any form without the expressed permission of H.C. Wainwright & Co., LLC. Additional information available upon request. H.C. Wainwright & Co., LLC does not provide individually tailored investment advice in research reports. This research report is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this research report. H.C. Wainwright & Co., LLC’s and its affiliates’ salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed in this research report. H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data on the company, industry or security discussed in the report. All opinions and estimates included in this report constitute the analyst’s judgment as of the date of this report and are subject to change without notice. Securities and other financial instruments discussed in this research report: may lose value; are not insured by the Federal Deposit Insurance Corporation; and are subject to investment risks, including possible loss of the principal amount invested.

( Companies Mentioned: AVXL:NASDAQ, )

Source: Dr. David Nierengarten 10/29/2024

Wedbush analysts Dr. David Nierengarten, Dennis Pak, and Dr. Martin Fan, in a research report published on October 29, 2024, maintained their Outperform rating on Kiniksa Pharmaceuticals Ltd. (KNSA:NASDAQ) with a price target of US$34.00. The report follows Kiniksa's Q3 2024 earnings announcement, which showed continued strong growth for Arcalyst.

The analysts highlighted the company's strong quarterly performance, stating, "Net product revenues of US$112.2MM (+73% y/y) slightly edged out our US$112.0MM estimate. Management's updated FY revenue guidance to US$410-US$420MM (previously US$405-US$415MM) implies Q4 revenue of US$115.5-US$125.5MM (3%-12% q/q growth)."

Regarding market penetration, the analysts noted, "More than 11% of patients in KNSA's target RP population of 14,000 patients that suffer from two or more recurrences are now actively on Arcalyst therapy, compared to 9% penetration at YE23." They added, "Notably, ~45% of all new prescriptions were written by repeat prescribers, which accounted for ~25% (640) of total prescriber base."

The analysts emphasized the growing duration of therapy, stating, "Importantly, average total duration of Arcalyst therapy in RP continues to grow, increasing to ~27 months as of 3Q24 from ~23 months as of 1Q24."

Regarding the company's pipeline, the report highlighted progress with abiprubart, noting, "Abiprubart's subcutaneous formulation and potential for once-monthly dosing should provide a greater dosing convenience relative to other agents and support uptake in a crowded but large market (300,000+ patients in the U.S.A.) assuming comparable efficacy."

The analysts addressed the stock's recent performance, stating, "We think today's share action reflects overoptimistic expectations investors may have had following the outsized Q2 sequential growth over a seasonally weak Q1. Net-net, we believe Arcalyst fundamentals remain strong and view current trading levels as an attractive entry point."

Wedbush's valuation methodology is based on a sum-of-parts approach. The analysts explained, "Our PT is derived from a sum-of-parts valuation for each of the company's clinical programs: an 8x multiple to KNSA's share of estimated US sales of Arcalyst in RP in 2027 and CAPS in 2025 (discounted back by 15%), and an 8x multiple to abiprubart's estimated sales in Sjogren's disease in 2029/30 (discounted back by 35%)."

In conclusion, Wedbush's maintenance of its Outperform rating and US$34 price target reflects confidence in Kiniksa's commercial execution with Arcalyst and pipeline potential. The share price at the time of the report of US$23.76 represents a potential return of approximately 43% to the analysts' target price, suggesting a significant upside as the company continues to expand its market penetration and advance its pipeline.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
2. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for Wedbush, Kiniksa Pharmaceuticals, October 29, 2024

Analyst Certification We, David Nierengarten, Dennis Pak and Martin Fan, certify that the views expressed in this report accurately reflect our personal opinions and that we have not and will not, directly or indirectly, receive compensation or other payments in connection with our specific recommendations or views contained in this report.

Company Specific Disclosures This information is subject to change at any time. 1. WS makes a market in the securities of Kiniksa Pharmaceuticals.

Wedbush disclosure price charts are updated within the first fifteen days of each new calendar quarter per FINRA regulations. Price charts for companies initiated upon in the current quarter, and rating and target price changes occurring in the current quarter, will not be displayed until the following quarter. Additional information on recommended securities is available on request. Disclosure information regarding historical ratings and price targets is available: Research Disclosures *WS changed its rating system from (Strong Buy/ Buy/ Hold/ Sell) to (Outperform/ Neutral/ Underperform) on July 14, 2009. Applicable disclosure information is also available upon request by contacting the Research Department at (212) 833-1375, by email to leslie.lippai@wedbush.com. You may also submit a written request to the following: Wedbush Securities, Attn: Research Department, 142 W 57th Street, New York, NY 10019.

OTHER DISCLOSURES The information herein is based on sources that we consider reliable, but its accuracy is not guaranteed. The information contained herein is not a representation by this corporation, nor is any recommendation made herein based on any privileged information. This information is not intended to be nor should it be relied upon as a complete record or analysis: neither is it an offer nor a solicitation of an offer to sell or buy any security mentioned herein. This firm, Wedbush Securities, its officers, employees, and members of their families, or any one or more of them, and its discretionary and advisory accounts, may have a position in any security discussed herein or in related securities and may make, from time to time, purchases or sales thereof in the open market or otherwise. The information and expressions of opinion contained herein are subject to change without further notice. The herein mentioned securities may be sold to or bought from customers on a principal basis by this firm. Additional information with respect to the information contained herein may be obtained upon request. Wedbush Securities does and seeks to do business with companies covered in its research reports. Thus, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Please see pages 3–7 of this report for analyst certification and important disclosure information. Retail Investors The information provided is for general informational purposes only and should not be considered an individual recommendation or personalized investment advice. The companies/investments mentioned may not be suitable for everyone. Each investor needs to review their own respective situation(s) before making any investment decisions. All expressions of opinion are subject to change without notice due to shifting market(s), economic or political conditions. Investment involves risks including the risk of principal. Past performance is no guarantee of future results and the opinions presented cannot be viewed as an indicator of future performance.

( Companies Mentioned: KNSA:NASDAQ, )

Source: Dr. Douglas Loe 10/31/2024

Leede Financial analysts Dr. Douglas Loe and Siew Ching Yeo, in a research report published on October 30, 2024, maintained their Speculative Buy rating on ProMIS Neurosciences Inc. (PMN:TSX; PMN:NCM) with a price target of US$9.50. The report follows ProMIS's presentation of interim Phase I data for PMN310, its Alzheimer's disease (AD) candidate, at the Clinical Trials on Alzheimer's Disease (CTAD) conference.

The analysts highlighted the positive safety and pharmacokinetic (PK) data, stating, "We were encouraged (though not overly surprised) to see that the mAb was well-tolerated at all five test doses ranging from 2.5mg/kg-to-40mg/kg." They added, "PK analysis of all of these patient cohorts in this single-ascending dose (SAD) trial suggests that once-monthly dosing may be sufficient to sustain mAb levels both in plasma and in cerebrospinal fluid over time."

Regarding dosing efficacy, the analysts noted, "Importantly, ProMIS indicated in the Jul/24 update that even at 2.5mg/kg dosing, PMN310 levels in CSF were over 100x higher than predicted to be necessary to bind to all beta-amyloid oligomers that could accumulate in CSF in diseased patients."

The analysts emphasized the significance of recent industry developments, particularly AbbVie's acquisition of Aliada Therapeutics, stating, "AbbVie's tangible interest in Phase I-stage AD assets shows us that ProMIS could itself be attractive to future suitors if/when it can document direct impact on cognitive impairment in diseased patients."

The report highlighted ProMIS's financial position following its recent equity offering, noting that the company raised US$30.3M with multiple layers of warrant coverage tied to development milestones.

Leede Financial's valuation methodology combines multiple approaches. The analysts explained, "We are maintaining our Speculative Buy rating and one-year PT of US$9.50 on PMN, with our valuation still based on NPV (30% discount rate) and multiples of our F2029 EBITDA/fd EPS forecasts."

They added, "By direct comparison to Aliada's US$1.4B value, PMN shares would notionally be valued on a fully-diluted basis at US$17.65/shr."

In conclusion, Leede Financial's maintenance of their Speculative Buy rating and US$9.50 price target reflects confidence in ProMIS's development of PMN310 and its potential in the Alzheimer's disease market. The share price at the time of the report of US$1.03 represents a potential return of approximately 822% to the analysts' target price, highlighting the significant upside potential if the company's clinical development plans prove successful.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of ProMIS Neurosciences Inc.
2. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
3. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for Leede Financial Inc., ProMIS Neurosciences Inc., October 30, 2024

Important Information and Legal Disclaimers Leede Financial Inc. (Leede) is a member of the Canadian Investment Regulatory Organization (CIRO) and a member of the Canadian Investor Protection Fund (CIPF). This document is not an offer to buy or sell or a solicitation of an offer to buy or sell any security or instrument or to participate in any particular investing strategy. Data from various sources were used in the preparation of these documents; the information is believed but in no way warranted to be reliable, accurate and appropriate. All information is as of the date of publication and is subject to change without notice. Any opinions or recommendations expressed herein do not necessarily reflect those of Leede. Leede cannot accept any trading instructions via e-mail as the timely receipt of e-mail messages, or their integrity over the Internet, cannot be guaranteed. Dividend yields change as stock prices change, and companies may change or cancel dividend payments in the future. All securities involve varying amounts of risk, and their values will fluctuate, and the fluctuation of foreign currency exchange rates will also impact your investment returns if measured in Canadian Dollars. Past performance does not guarantee future returns, investments may increase or decrease in value, and you may lose money. Leede employees may buy and sell shares of the companies that are recommended for their own accounts and for the accounts of other clients. Disclosure codes are used in accordance with Policy 3600 of CIRO.

Description of Disclosure Codes 1. Leede and its affiliates collectively beneficially own 1% or more of any class of equity securities of the company as of the end of the preceding month or the month prior to the preceding month if the report was issued prior to the 10th. 2. The analyst or any associate of the analyst responsible for the report or public comment hold shares or is short any of the company's securities directly or through derivatives. 3. Leede or a director or officer of Leede or any analyst provided services to the company for remuneration other than normal investment advisory or trade execution services within the preceding 12 months. 4. Leede provided investment banking services for the company during the 12 months preceding the publication of the research report. 5. Leede expects to receive or intends to seek compensation for investment banking services in the next three months. 6. The analyst preparing the report received compensation based upon Leede investment banking revenues for this issuer within the preceding 12 months. 7. The director, officer, employee, or research analyst is an officer, director or employee of the company, or serves in an advisory capacity to the company. 8. Leede acts as a market maker of the company. 9. The analyst has conducted a site visit and has viewed a major facility or operation of the issuer. 10. The company has paid for all, or a material portion, of the travel costs associated with the site visit by the analyst.

Dissemination All final research reports are disseminated to existing and potential institutional clients of Leede Financial Inc. (Leede) in electronic form to intended recipients thorough e-mail and third-party aggregators. Research reports are posted to the Leede website and are accessible to customers who are entitled to the firm’s research. Reproduction of this report in whole or in part without permission is prohibited.

Research Analyst Certification The Research Analyst(s) who prepare this report certify that their respective report accurately reflects his/her personal opinion and that no part of his/her compensation was, is, or will be directly or indirectly related to the specific recommendations or views as to the securities or companies. Leede Financial Inc. (Leede) compensates its research analysts from a variety of sources and research analysts may or may not receive compensation based upon Leede investment banking revenue.

Canadian Disclosures This research has been approved by Leede Financial Inc. (Leede), which accepts sole responsibility for this research and its dissemination in Canada. Leede is registered and regulated by the Canadian Investment Regulatory Organization (CIRO) and is a member of the Canadian Investor Protection Fund (CIPF). Canadian clients wishing to effect transactions in any designated investment discussed should do so through a Leede Registered Representative.

U.S. Disclosures This research report was prepared by Leede Financial Inc. (Leede). Leede is registered and regulated by the Canadian Investment Regulatory Organization (CIRO) and is a member of the Canadian Investor Protection Fund (CIPF). This report does not constitute an offer to sell or the solicitation of an offer to buy any of the securities discussed herein. Leede is not registered as a broker-dealer in the United States and is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. Any resulting transactions should be effected through a U.S. broker-dealer.

( Companies Mentioned: PMN:TSX; PMN:NCM, )

Source: Dr. David Nierengarten 11/07/2024

TScan Therapeutics Inc. (TCRX:NASDAQ) Phase 1 ALLOHA study, evaluating its lead therapeutic candidates TSC-100 and TSC-101 in hematologic malignancies, showed patients continuing to have a positive response after one year, reported Wedbush analyst Dr. David Nierengarten in a Nov. 5 research note. TSC-100 and TSC-101 are T-cell receptor-engineered T-cell therapies (TCR-Ts).

"We see a catalyst-rich next few months ahead with data building in prominence on stock impact," Nierengarten wrote.

87% Return Potential

Wedbush has a US$10 per share target price on the Massachusetts-based biotech, trading at the time of the report at about US$5.36 per share, noted the analyst. The difference between these figures implies an 87% return potential for investors.

TScan Therapeutics remains rated Outperform.

Durability of Response Data

Nierengarten presented the clinical trial's latest results. As of the July 8, 2024 data cutoff date, in Phase 1 of ALLOHA, 16 patients with hematologic tumors had been administered TSC-100 or TSC-101, and 11 patients had been given a placebo. Median follow-ups had occurred at 5.8 months and 5.3 months, respectively.

At the time, none of the patients in the treatment arm had had a relapse. In the control arm, however, three, or 27% of, the 11 patients had, and the median time to relapse was 159 days. The analyst explained that this is typical for patients receiving a hematopoietic stem cell transplant after reduced-intensity conditioning.

One year out from treatment, five patients were evaluable, and all remained relapse free and minimal residual disease negative at the time. These data underscore the durability of response to this TCR-T treatment, Nierengarten commented. Its safety profile was shown to be favorable still, with no patients experiencing dose-limiting toxicities or adverse events associated with allogeneic hematopoietic cell transplantation.

"Enrollment continues in dose expansion cohorts, and results could support a registrational trial as early as 2025, pending regulatory feedback," Nierengarten wrote.

On the Horizon

TScan Therapeutics has several catalysts related to its clinical programs on the horizon, which Nierengarten listed.

On Nov. 8 and 9, the company will present preclinical data in the poster sessions at the annual Society for Immunotherapy of Cancer meeting. One poster will show in vitro combinatorial data for T-Plex, TScan's cellular therapy for treating solid tumors. It is comprised of two to three different TCR-Ts that target different tumor antigens on different human leukocyte antigen (HLA) types.

A second poster will detail the expansion of ImmunoBank, the biotech's diverse bank of therapeutic T-cell receptors (TCRs) that recognize diverse targets and are associated with multiple HLA types. The third will depict development of a target agnostic platform to evaluate how TCR-Ts affect primary human tissues.

On Dec. 9, TScan Therapeutics will present updated one-year data from ALLOHA, at the American Society for Hematology Annual Meeting in December.

By year-end, the biotech will announce initial data from administering singleplex therapy, cell therapy engineered using a single TCR, to patients with solid tumors. This treatment is being given to establish safety before administering multiplex therapy, cell therapy engineered from multiple TCRs.

In 2025, TScan Therapeutics will provide long-term duration of response data for multiplex therapy in solid tumors and will potentially commence a registrational trial for TSC-100 and TSC-101.

Sign up for our FREE newsletter at: www.streetwisereports.com/get-news

Important Disclosures:

1. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company.
2. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

Disclosures for Wedbush, TScan Therapeutics Inc., November 5, 2024

Analyst Certification We, David Nierengarten, Martin Fan and Dennis Pak, certify that the views expressed in this report accurately reflect our personal opinions and that we have not and will not, directly or indirectly, receive compensation or other payments in connection with our specific recommendations or views contained in this report.

Company Specific Disclosures This information is subject to change at any time. 1. WS makes a market in the securities of TScan Therapeutics, Inc.. 6. WS is acting as a financial advisor for TScan Therapeutics, Inc..

Wedbush disclosure price charts are updated within the first fifteen days of each new calendar quarter per FINRA regulations. Price charts for companies initiated upon in the current quarter, and rating and target price changes occurring in the current quarter, will not be displayed until the following quarter. Additional information on recommended securities is available on request. Disclosure information regarding historical ratings and price targets is available: Research Disclosures *WS changed its rating system from (Strong Buy/ Buy/ Hold/ Sell) to (Outperform/ Neutral/ Underperform) on July 14, 2009. Applicable disclosure information is also available upon request by contacting the Research Department at (212) 833-1375, by email to leslie.lippai@wedbush.com. You may also submit a written request to the following: Wedbush Securities, Attn: Research Department, 142 W 57th Street, New York, NY 10019.

OTHER DISCLOSURES The information herein is based on sources that we consider reliable, but its accuracy is not guaranteed. The information contained herein is not a representation by this corporation, nor is any recommendation made herein based on any privileged information. This information is not intended to be nor should it be relied upon as a complete record or analysis: neither is it an offer nor a solicitation of an offer to sell or buy any security mentioned herein. This firm, Wedbush Securities, its officers, employees, and members of their families, or any one or more of them, and its discretionary and advisory accounts, may have a position in any security discussed herein or in related securities and may make, from time to time, purchases or sales thereof in the open market or otherwise. The information and expressions of opinion contained herein are subject to change without further notice. The herein mentioned securities may be sold to or bought from customers on a principal basis by this firm. Additional information with respect to the information contained herein may be obtained upon request. Wedbush Securities does and seeks to do business with companies covered in its research reports. Thus, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision. Please see pages 3–7 of this report for analyst certification and important disclosure information. Retail Investors The information provided is for general informational purposes only and should not be considered an individual recommendation or personalized investment advice. The companies/investments mentioned may not be suitable for everyone. Each investor needs to review their own respective situation(s) before making any investment decisions. All expressions of opinion are subject to change without notice due to shifting market(s), economic or political conditions. Investment involves risks including the risk of principal. Past performance is no guarantee of future results and the opinions presented cannot be viewed as an indicator of future performance.

( Companies Mentioned: TCRX:NASDAQ, )

Skyharbour Resources Ltd. (SYH:TSX.V; SYHBF:OTCQX; SC1P:FSE) announced it has entered into an agreement with Hatchet Uranium Corp. to acquire interest in several of its projects. One analyst says the "spotlight" is on uranium juniors as the energy transition drives a heightened demand for power sources.

Poet Amanda Gorman speaks at the inauguration of U.S. President Biden on the West Front of the U.S. Capitol on Wednesday.; Credit: Alex Wong/Getty Images

When Amanda Gorman, a 22-year-old poet from Los Angeles, took to the stage on Wednesday, it was immediately clear why the new president had chosen her as his inaugural poet.

Gorman echoed, in dynamic and propulsive verse, the same themes that Biden has returned to again and again and that he wove throughout his inaugural address: unity, healing, grief and hope, the painful history of American experience and the redemptive power of American ideals.

Where Biden said, "We must end this uncivil war," Gorman declared, "We lay down our arms so we can reach out our arms to one another."

And where Biden called for an American story of "love and healing" and "greatness and goodness," Gorman saw strength in pain: "Even as we grieved, we grew," she said.

Gorman opened by acknowledging the reasons why hope can be challenging. "Where can we find light in this never-ending shade?" she asked.

But she continued: "And yet, the dawn is ours before we knew it. Somehow we do it. Somehow we weathered and witnessed a nation that isn't broken but simply unfinished."

She acknowledged the power of her own presence on the stage in "a country and a time where a skinny black girl descended from slaves and raised by a single mother can dream of becoming president, only to find herself reciting for one."

Like Obama inaugural poet Richard Blanco, who invoked the grand sweep of American geography in a call for unity in "One Today," Gorman dedicated a portion to "every corner called our country" from the South to the Midwest. She ended with an invitation to "step out of the shade."

"The new dawn blooms as we free it," she said. "For there is always light, if only we are brave enough to see it – if only we are brave enough to be it."

Gorman was following in the footsteps of poets like Blanco, Robert Frost and Maya Angelou as she composed the poem "The Hill We Climb" for the inauguration.

She also took her cues from orators like Frederick Douglass, Abraham Lincoln and Martin Luther King, Jr. — people who knew a thing or two about calling for hope and unity in times of despair and division.

Gorman told NPR she dug into the works of those speakers (and Winston Churchill, too) to study up on ways "rhetoric has been used for good." Over the past few weeks, she composed a poem that acknowledges the previous president's incitement of violence, but turns toward hope.

"The Hill We Climb" reads, in part:

We've seen a force that would shatter our nation rather than share it,

Would destroy our country if it meant delaying democracy.

And this effort very nearly succeeded.

But while democracy can be periodically delayed,

It can never be permanently defeated.

In this truth, in this faith, we trust.

For while we have our eyes on the future,

history has its eyes on us.

Gorman, like Biden, had a speech impediment as a child. (Biden had a stutter; Gorman had difficulty pronouncing certain sounds.) She told NPR's Steve Inskeep that her speech impediment was one reason she was drawn to poetry at a young age.

"Having an arena in which I could express my thoughts freely was just so liberating that I fell head over heels, you know, when I was barely a toddler," she said.

For Gorman, a former National Youth Poet Laureate, her struggle to speak provided a connection not only to the incoming president, but also to previous inaugural poets, too.

"Maya Angelou was mute growing up as a child and she grew up to deliver the inaugural poem for President Bill Clinton," she says. "So I think there is a real history of orators who have had to struggle with a type of imposed voicelessness, you know, having that stage in the inauguration."

Barack Obama, Bill Clinton and John F. Kennedy were the only presidents in the past who chose to have poems read at their inaugurations. You can read all the previous poems here.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Halima Aden attends the premiere of Netflix's Travis Scott: Look Mom I Can Fly at Barker Hangar on Aug. 27, 2019, in Santa Monica, Calif.; Credit: Rich Fury/Getty Images

For Halima Aden, the decision to walk away from a career as the world's first hijab-wearing supermodel was fairly clear cut. She's felt used for so long, she says — by the modeling industry and by UNICEF, the organization she was photographed by as a child in a refugee camp in Kenya and later served as an ambassador for.

Aden has been featured on the covers of Vogue, Elle and Allure magazines. And she walked the runway for Rihanna's Fenty Beauty and Kanye West's Yeezy.

She tells Morning Edition host Rachel Martin she wanted to be a role model for young girls while being true to herself, but she wasn't accomplishing either. Modeling, she realized, was in "direct conflict" with who she is.

"I'm not a cover girl, I'm Halima from Kakuma," she says. "I want to be the reason why girls have confidence within themselves, not the reason for their insecurity."

Aden was raised in the Kakuma refugee camp in northwestern Kenya. She and her family moved to Minnesota in 2004 when she was 7.

It was there her journey as a model began, competing for Miss Minnesota USA in 2016, seeking a scholarship. She finished in the semifinals, and says from there, modeling "fell from the sky" into her lap.

Interview Highlights

You saw [modeling] not just as a chance to wear gorgeous clothes and to have your photo in magazines but also as a way to help people.

Growing up in America, not seeing representation, not seeing anybody who dressed like me look like me, it did make me feel like, wow, what's wrong with me, you know? And I'm sure if I had if I would have had representation growing up, I would have been so much more confident to wear my hijab, to be myself, to be authentic. But to be that person, to grow up and be on the cover of magazines, I've covered everything from Vogue to Allure, some of the biggest publications in fashion. And yet I still couldn't relate personally to my own image because that's not who I really am. That's not how I really dress. That's not how my hijab really looks. And, you know, fashion, it can be a very creative field, and I completely appreciate that. But my hijab was just getting spread so thin that I knew I had to give it all away, give it up. I'm not a cover girl. I am Halima from Kakuma. I want to be the reason why girls have confidence within themselves, not the reason for their insecurity.

When you say your hijab was being kind of styled out of existence, what passed for a hijab as you were walking down those runways?

Everything. Oh, my goodness. I had jeans at one point on my head as a hijab. I had Gucci pants styled as a turban. It just didn't even make sense, and I felt so far removed from the image itself.

During the pandemic you decided to walk away from fashion and UNICEF. Was it a complicated decision?

I'll be honest with you, the feelings that I've had towards the fashion industry and UNICEF, it was just multiplying as the years went on, so it was just festering. You know, because the fashion industry is very known to use these young girls and boys while their young, age 14 to like 24, I think is the average career of a model. And then they just replace them and move on to a newer model. And same with UNICEF. They've been photographing me and using me since the time I was a baby in a refugee camp. I remember getting those headshots taken and it made me feel, it's very dehumanizing. And so I wanted to show UNICEF, too. How does it feel to be used? It's not a good feeling. And so let's stop using people.

What are you going to do [next]?

For me right now, I don't know what's next. And that's OK. That's OK, because I'm young and I have time to figure it out. And I'm grateful. I'm grateful to the people that I've met. I'm grateful to the agents that I worked with. I'm grateful for the experiences I was able to have these last four years. But at the same time, I just am also grateful that I don't have to do that anymore because it was in direct conflict with who I am as an individual, as a human being.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Live-event spaces, like the Sound Nightclub in Los Angeles, have been waiting months for emergency relief.; Credit: Mario Tama/Getty Images

Owners of live-music venues, theaters, museums and other businesses covered under the Shuttered Venue Operators Grant, or SVOG, can expect to see money by the end of May. This is according to an update from the Small Business Administration, which has been handling the SVOG program's bumpy rollout.

An SBA spokesperson said in an email that since the portal to apply for these grants opened a week ago, 10,300 applications have been submitted (another 12,000 have been started but not completed). The vast majority of those applications were from "Live venue operators or promoters," followed by performing arts organizations and then movie theaters.

The SBA has been reviewing applications and said in a statement that "applicants will receive notice of awards this month," with disbursement by the end of May if the applicant responds in a "timely manner to the notice of award."

The SVOG program is a $16 billion emergency relief program that then-President Donald Trump signed into law in late December 2020. It was a bipartisan effort to get aid money to struggling music venues and other arts and live-event spaces that have been hit hard by the coronavirus struggles. But for an emergency relief program, it has taken months to get money in the hands of business owners holding off landlords, insurance companies and other creditors. Those owners spent early 2021 waiting on an official announcement of when they could apply for the grant money while compiling any documents and paperwork they thought they might need. Then once the application site was up and running, it crashed and was closed.

Even as large festivals roll out throughout the U.S. and bands announce tours for later in the year, many small live-event spaces are still at risk of closing. The National Independent Venue Association, one of the most vocal groups lobbying for support for live-music venues, has long stated that 90% of its members would be forced to close without any aid — which would hurt nearby bars, restaurants and shops, not to mention the large apparatus that is the live touring-arts industry.

This content is from Southern California Public Radio. View the original story at SCPR.org.

#FreeBritney activists protest outside the Los Angeles Superior Court during one of Britney Spears' hearings this April.; Credit: Matt Winkelmeyer/Getty Images

Pop star Britney Spears hasn't been in charge of her personal life or her finances for 13 years — that's how long she has been in a court-dictated legal arrangement called a conservatorship.

But on Wednesday, the artist will be speaking directly, albeit from a remote location, to a Los Angeles Superior Court judge about her situation. What exactly she intends to say in her appearance and what her goals might be are anyone's guess.

Before then, here's a quick look at what conservatorships are and why they exist, the specifics of Spears' arrangements, the #FreeBritney movement and what Spears and others have said publicly — and privately — about her conservatorship.

What is a conservatorship, and why does one get put in place?

Typically, legal and financial conservatorships are arranged for people who are unable to make their own decisions in their own best self-interest, such as in the case of an elderly person or someone with some kind of cognitive impairment.

Why does Britney Spears have one?

The exact reasons that the 39-year-old Spears is under a conservatorship have not been publicly disclosed. She lost her autonomy 13 years ago, in 2008, after apparently suffering a mental health crisis.

During the time that Spears has lived under this arrangement, though, she has released four albums (two of which, 2008's Circus and 2011's Femme Fatale, achieved platinum sales); appeared as a judge on both The X Factor and American Idol; and had a four-year residency in Las Vegas that reportedly grossed close to $138 million. Those accomplishments don't exactly line up with the typical profile of someone unable to look after themselves.

What does Spears' conservatorship cover?

Essentially, it controls all the major aspects of Spears' life, including decisions regarding her financial, medical and personal well-being. The conservators also oversee visitation arrangements with her two teenage sons, who are under the full custody of her ex-husband, Kevin Federline.

According to Forbes, Spears' current net worth is around $60 million.

Who controls Spears' conservatorship?

Up until recently, both the financial and personal arms of the conservatorship were controlled by Spears' father, Jamie Spears.

In 2020, her lawyer, Samuel D. Ingham III, stated in a filing that Spears "strongly opposed" her father as conservator and that she refused to perform if he remained in charge of her career. Spears asked the court for her father to be suspended from his role as conservator. (He had temporarily stepped away in 2019 for health reasons.)

In February, Los Angeles Superior Court Judge Brenda Penny overruled an objection from Jamie Spears to having a third party help look after his daughter's financial affairs. A wealth-management company, Bessemer Trust, is now a co-conservator for the financial side of Spears' situation. But Jamie Spears is still the main conservator for all other aspects of Spears' arrangement.

Why is Spears planning to talk to the court now?

Back in April, Spears' legal team asked Penny to allow her to speak to the court directly about the conservatorship, and they agreed that June 23 would be the date for this to happen. At the time, Ingham did not disclose why Spears wants to speak or what she intends to say.

Has Spears ever asked for the conservatorship to end?

Up until now, Spears has never voiced a desire for the conservatorship to be removed completely — at least not publicly. In a court filing, she has stated that the conservatorship "rescued her from a collapse, exploitation by predatory individuals and financial ruin" and allowed her to "regain her position as a world class entertainer."

But on Tuesday afternoon, The New York Times reported that it had obtained confidential court records that purport to show that Spears has opposed the conservatorship privately for years. The Times quoted a 2016 report from a court investigator assigned to Spears' case, in which the investigator wrote that Spears told her that the conservatorship had "become an oppressive and controlling tool against her" and that she wanted the arrangement to end quickly.

According to the Times, Spears told the court in 2019 that the conservatorship had forced her into a stay at a mental health facility, as well as into making public performances against her will. The article further reported that the conservatorship had dictated Spears' friendships, her dating life and her spending habits, even preventing her from refinishing kitchen cabinets according to her taste.

As early as 2014, the article states, Spears wanted to consider removing her father from his prime role in the conservatorship, citing his reportedly heavy drinking.

Does Spears herself support the #FreeBritney movement?

Certain Spears fans have organized themselves into a grassroots movement — #FreeBritney — to help Spears regain autonomy over her life. The dynamics between Spears and her dedicated #FreeBritney fans are murky, as are her various declarations on social media.

In a court filing last September, her lawyer, Ingham, wrote: "At this point in her life when she is trying to regain some measure of personal autonomy, Britney welcomes and appreciates the informed support of her many fans."

On the other hand, Spears to date has never publicly asked to be released from the conservatorship and regain her autonomy — which is the main goal of #FreeBritney.

A very sympathetic New York Times television documentary, Framing Britney Spears, debuted on FX in February. The project reckons with the way the media, comedians and the music industry itself characterized Spears during her ascent to global fame and during her later, very public struggles — and it also profiles some #FreeBritney activists.

After it aired, Spears wrote on Instagram: "My life has always been very speculated [sic] ... watched ... and judged really my whole life !!! ... I didn't watch the documentary but from what I did see of it I was embarrassed by the light they put me in ... I cried for two weeks and well .... I still cry sometimes !!!!"

Some #FreeBritney supporters don't believe Spears writes her own Instagram messages, leaving them to speculate about the pop star's true feelings. But Spears reportedly told TMZ in April that she writes her own captions.

What's next for Britney Spears?

Unclear. In an Instagram video posted last week, a visibly jittery Spears professed to be answering fans' most burning questions, including her shoe size and her favorite business trip (answer: "a trip to Italy [to] Donatella Versace. ... She fined [sic] and dined us").

The last question Spears put forward to herself was a crucial one: Would she ever return to the stage again?

"I have no idea," she said. "I'm having fun right now. I'm in transition in my life, and I'm enjoying myself."

This content is from Southern California Public Radio. View the original story at SCPR.org.

A judge has denied Britney Spears' request to remove her father, Jamie Spears (left), as a co-conservator.; Credit: /AP

A Los Angeles Superior Court judge signed an order Wednesday denying Britney Spears' request to have her father, Jamie Spears, removed from the financial aspects of her conservatorship.

Judge Brenda Penny denied the request, which was first filed by Spears' attorney, Samuel D. Ingham III, last November. The judge's decision comes after the singer appeared in court last Wednesday to make a direct appeal to the court. In that emotional statement, Spears said that she was being exploited and "bullied" by the conservatorship — and specifically, by her father.

Until recently, both the financial and personal arms of the conservatorship were controlled by Spears' father, Jamie Spears.

Last year, Ingham stated in a filing that Spears "strongly opposed" her father as conservator, and that she refused to perform if he remained in charge of her career.

In February, Judge Penny allowed a wealth-management company, Bessemer Trust, to come in as a co-conservator for the financial arm of Spears' arrangement. Jamie Spears remains the main conservator for all other aspects of Spears' conservatorship.

The next hearing in the case is currently scheduled for July 14. It is possible that Spears will submit a petition for the conservatorship to be terminated. In her comments to Judge Penny last week, Spears said that she had been unaware that she could take such an action. "I didn't know I could petition the conservatorship to end it," she said. "I'm sorry for my ignorance, but I honestly didn't know that."

This content is from Southern California Public Radio. View the original story at SCPR.org.

Vox Royalty Corp. (VOXR:TSX.V) reported its Q3 2024 financial results. Read more on how strong cash flow growth, record production, and key project milestones are driving these results.

Global Analyst Adrian Day reviews results from two high-quality companies, a gold miner and a global blue chip. He also looks at changes in gold trends.

Tim Cook, chief executive officer of Apple Inc., speaks during an event in 2018. Apple is one of 310 companies calling on the Biden administration to slash carbon emissions.; Credit: David Paul Morris/Bloomberg via Getty Images

More than 300 businesses have signed an open letter calling on the Biden administration to reduce greenhouse gas emissions in the United States to at least half of 2005 levels by 2030. That would nearly double a previous target set by former President Barack Obama in 2015, who pledged a 25 to 28% reduction by 2025.

The United States is not currently on track to meet either goal.

The signatories include some of largest companies in the United States, including Walmart, Apple, McDonald's and Starbucks. "A bold 2030 target is needed to catalyze a zero-emissions future, spur a robust economic recovery, create millions of well-paying jobs, and allow the U.S. to 'build back better' from the pandemic," the letter said, echoing the president's economic recovery slogan.

A 50% reduction target would put the Biden administration in line with what groups such as the United Nations and National Academies of Science say is necessary to mitigate the worst impacts of climate change.

In a March statement calling for the same reductions target, the environmental advocacy group Natural Resources Defense Council said such a plan would "help pull the country out of the pandemic-induced recession by putting millions of Americans to work" and inspire more ambitious international climate action ahead of a major United Nations climate conference this November.

Like President Joe Biden's campaign promise to guide the United States to carbon-neutrality by the middle of the century, a 50% emissions reduction target would require steeper emissions cuts than the country has ever achieved.

In 2019, greenhouse gas emissions were approximately 13% below 2005 levels, a decrease of just 1.8% from the previous year.

The Biden administration has identified climate action as one of its top four priorities and has named prominent, experienced Washington insiders, including former Secretary of State John Kerry and former EPA administrator Gina McCarthy, to oversee climate policy efforts at the White House.

As NPR's Danielle Kurtzleben has previously reported, activists on the left are cautiously optimistic about the administration's climate plan after expressing doubts about Biden's climate record during the Democratic primary.

Sunrise Movement, a youth-led climate group that champions the Green New Deal, gave candidate Biden's initial climate plan an "F" grade. Now, the group's executive director Varshini Prakash is publicly celebrating his administration's latest climate-focused $2 trillion infrastructure bill — including its commitment to spend 40% of the infrastructure plan's money on disadvantaged communities and launch a jobs program called the Civilian Climate Corps.

New York Democratic Rep. Alexandria Ocasio-Cortez told NPR earlier this month that she feels that Biden has ultimately come around to the side of progressives on climate issues. She said: "As much as I think some parts of the party try to avoid saying 'Green New Deal' and really dance around and try to not use that term, ultimately, the framework I think has been adopted."

The emphasis on climate comes as a sharp departure from the Trump administration, which withdrew the United States from the Paris Agreement and set no emissions reductions targets.

Signatories to the Paris deal, which Biden rejoined on the day he was sworn into office, are all required to set these targets — formally known as nationally determined contributions, or NDCs.

The agreement also encourages nations to revise their goals every five years, in hopes that the proposals become more ambitious as the cost of environmental reform goes down.

Since the Paris agreement was first agreed to in 2015, though, just fifty of the deal's nearly 200 signatories have submitted revised targets. A recent U.N. analysis of international climate action found that many countries were doing far too little to reduce emissions for the world to avoid the worst effects of climate change.

So far, the White House has not indicated exactly how ambitious their plan will be. An announcement is expected in the coming days as the White House prepares for its Earth Day climate summit with world leaders, scheduled for Thursday, April 22.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Florida Gov. Ron DeSantis speaks to the media about the cruise industry during a press conference at PortMiami in April. DeSantis faces criticism for failing to do all he could on Florida's biggest environmental threat: climate change.; Credit: Joe Raedle/Getty Images

Brick by brick, the stucco shell of a new flood-resilient public works building is taking shape blocks from the beach, the most visible sign yet of a small community's enormous task staving off the rising sea.

"This is actually the highest point in the city," Satellite Beach City Manager Courtney Barker said, adding that right next door to the new public works building will be a new fire station.

It's a close-knit community established by rocket scientists south of Kennedy Space Center, on a low-slung barrier island between the Atlantic Ocean and Indian River Lagoon.

By 2040, community leaders expect significant impacts associated with climate change. Already flooding is a problem, and beach-front homes perch precariously atop a sand dune left exposed after a series of storms and hurricanes washed away a sea wall.

The needs are great, and in Gov. Ron DeSantis, Barker sees a potential ally.

"At least he talks about climate change as actually being real, so that's good," she said. "And he's putting money toward it so that's encouraging."

But Barker also feels DeSantis is doing only part of the job.

"We desperately need to grow up as a state and realize that we need to get our emissions down," Barker said.

Since his election in November 2018, DeSantis is making good on some of his environmental promises, including what he likes to call "resilience," a new buzzword for climate adaptation. But as the governor prepares for a reelection bid in 2022, and is seen as a potential Republican frontrunner for the presidency in 2024, DeSantis faces criticism for failing to do all he could on Florida's biggest environmental threat: climate change.

Some of his critics acknowledge that the $1 billion Resilient Florida plan he announced in January could be a first step toward helping some communities pay for adaptation. But critics also point out that DeSantis has done almost nothing to put Florida on a path to scaling back the state's heavy reliance on fossil fuels.

"I would give him probably a C-minus," said former Republican Gov. Charlie Crist, who served from 2007 to 2011, and now represents St. Petersburg in the U.S. House of Representatives as a Democrat.

Crist still gets plaudits from environmentalists for his administration's climate initiatives, including a cap-and-trade system to curb carbon emissions and an executive order that was intended to put the state on a path to reducing its greenhouse gas emissions 80% by 2050. But those were basically abandoned by Gov. Rick Scott, the Republican now serving in the U.S. Senate.

Crist, who switched parties and this week announced he is running for governor in 2022, said DeSantis should be "encouraging renewables such as wind energy, solar energy, and particularly solar. I mean, my goodness, we're the Sunshine State."

DeSantis' press office declined to make the governor available for an interview and did not respond to written questions.

In comments at two press conferences earlier this year, the governor cited his support for spending hundreds of millions of dollars on water projects and Everglades restoration as evidence of his environmental credentials, while promising to double down on funding for coastal resilience.

Florida needs "to tackle the challenges posed by flooding, intensified storm events [and] sea level rise," he said. "When you look at how an insurance market would view property insurance, and to see that Florida is leading and trying to get ahead of some of these impacts, we think it'll be a very smart thing to do."

Lawmakers have had their own ideas on how to handle climate threats, and have passed two bills that, when taken together, are similar to DeSantis' Resilient Florida proposal.

"It's not exactly as he said he wanted it, but it's close," said Jonathan Webber, deputy director of Florida Conservation Voters. "These are policies that need to happen. It would have been better if they happened 20 years ago."

"I am not a global warming person"

In his 2018 campaign, DeSantis appealed directly to supporters of former President Donald Trump, such as in this ad where he tells one of his children to "build the wall" with toy blocks. The environment was a major issue in that election.

Residents were grappling with a toxic red tide and blue-green algae crisis that made beaches and waterways unsafe, and left marine-life belly-up.

In recent years Floridians have also experienced deadly, devastating consequences of back-to-back major hurricanes.

All the while, advocates were highlighting likely links between the state's environmental woes and global warming.

Florida's climate challenges are among the biggest in the country. Beyond those related to hurricanes intensified by climate change, they include sea level rise, extreme heat, drought and increasing health threats from mosquito-borne diseases.

By its own numbers, the DeSantis administration predicts that with sea level rise, $26 billion in residential property statewide will be at risk of chronic flooding by 2045.

But in 2018, DeSantis let voters know that he had clear limits when it came to climate change.

"I am not in the pews of the church of the global warming leftists," DeSantis told reporters at one 2018 campaign stop. "I am not a global warming person. I don't want that label on me."

Early plaudits from environmentalists

Once in office, DeSantis won early plaudits for directives aimed at cleaning up water and helping Florida adapt to climate change. He appointed the first state resilience officer and the first chief scientist, and ordered Florida's Department of Environmental Protection to make sure its decisions were based on the best available science.

In 2019, they approved of DeSantis' order to his environmental regulators to oppose fracking, but he since has failed to get his Republican colleagues in the legislature to pass a statewide fracking ban, something he advocated for during his campaign. The state's oil and gas industry does not currently use fracking as a drilling method, but environmentalists are worried it might start doing so, resulting in water pollution.

Environmental groups also praised DeSantis in 2020 when the governor announced the state was backing a plan to buy 20,000 acres of the Everglades to prevent oil development there.

And they did the same when DeSantis backed spending $166 million in settlement money Florida received from Volkswagen on electric vehicle charging stations and cleaner electric buses. The money, part of a larger $14.7 billion settlement, came after the German automaker was caught lying about its cars' diesel emissions.

"Everyone was optimistic," said Susan Glickman, the Florida director for the Southern Alliance for Clean Energy. "I kept hearing an opening on climate."

Two years later, though, Glickman and other advocates are assessing DeSantis' climate record much like this: He's done more than previous Governor Scott, but that's not saying much.

DeSantis quietly replaced his chief science officer in March with Mark Rains, a professor, and chair and director of the School of Geosciences at the University of South Florida. But he never has replaced his chief resilience officer after she left for the Trump administration after only a few months in the position.

"Missing in action" on renewables

In many ways, it's what DeSantis hasn't done that defines his climate record. He has chosen not to use his bully pulpit to advocate for a clean-energy future, like his Democratic Party counterparts in the Southeast states of North Carolina and Virginia, or like the mayors of Orlando and Tampa.

DeSantis has also been "missing in action" in debate over bills this year in the Florida legislature that would undermine local government efforts to transition to clean energy, said Webber, with the Florida Conservation Voters group.

One such bill, that has passed the House and Senate and awaits DeSantis' consideration, would ban local governments from restricting fuel sources. The oil and gas industry has supported such measures around the country. They aim to block the push by climate activists to ban natural gas hook-ups in new buildings, and electrify them instead to reduce carbon emissions.

Of course, electrification only reduces emissions if it's powered by renewable energy. But Florida has no requirement that utilities provide a certain amount of that. Solar power accounts for only about 2.5% of the electricity produced by utilities, while they rely on fossil fuels for about 84%.

When DeSantis had a chance to appoint someone to the state's powerful Florida Public Service Commission, a regulatory body with a big say in state energy policy, he chose the Florida chairman of the American Legislative Exchange Council, a group known for its support of fossil fuels.

"We are very frustrated by the messaging, and the lack of acknowledgement of the root of the problem of all these issues," said Yoca Arditi-Rocha, executive director of The CLEO Institute, a nonprofit that focuses on climate science education.

"We need to acknowledge the warming temperatures and the rising seas are a result of our warming climate," she said. "We cannot adapt our way out of it. We need to aggressively tackle mitigation."

"What places can we not save?"

In Satellite Beach, Courtney Barker, the city manager who welcomes the governor's help with adapting to climate change, also wants to see him tackle the emissions side of the equation.

Besides moving the public works building and fire station to higher ground, the community is fortifying its system of flood control. Barker said the community needs more funding opportunities from the state.

"We're looking for assistance in helping us engineer our way out of it," she said.

Marine and climate scientist Jeff Chanton, of Florida State University, thinks there's too much emphasis on sea walls, which can cause beach erosion and destroy tidal zones vital to marine life, including crabs and turtles.

"An ideal governor would try to lessen the impacts of growth in this state, especially along our coastlines," he said.

Before her departure, Julia Nesheiwat, DeSantis' chief resilience officer, characterized the state's infrastructure as "outdated" in a report, and called its resilience strategy "disjointed."

For Thomas Ruppert, an attorney and coastal planning specialist with Florida Sea Grant, DeSantis' emphasis on hardening infrastructure ignores that — for some communities — the investments will be futile in staving off the inevitable.

"Ultimately, what we really need is to start talking seriously [about] what places can we not save? And what is an exit strategy? Because we have no idea," Ruppert said.

Barker hopes it doesn't come to that in Satellite Beach, where she grew up.

"It's personal to all of us, because I think everyone can look at their own hometown, and you can't imagine being anywhere else."

This story is a collaboration between Inside Climate News and WMFE Orlando, a member of ICN's National Reporting Network-Southeast.

This content is from Southern California Public Radio. View the original story at SCPR.org.

The Biden administration is opening the West Coast to offshore wind. Companies have largely focused on the East Coast, like this wind farm off Block Island, Rhode Island.; Credit: Don Emmert/AFP via Getty Images

The Biden administration plans to open the California coast to offshore wind development, ending a long-running stalemate with the Department of Defense that has been the biggest barrier to building wind power along the Pacific Coast.

The move adds momentum to the administration's goal of reaching 100% carbon-free electricity by 2035, coming just weeks after the country's first large-scale offshore wind farm was approved off the coast of New England. Today, the country has just a handful of offshore wind turbines in the Atlantic Ocean, with around a dozen wind farms being developed in federal waters off the East Coast.

"It's an announcement that will set the stage for the long term development of clean energy and the growth of a brand new made-in-America industry," says national climate adviser Gina McCarthy. "Now we're thinking big and thinking bold."

The agreement identifies two sites off Central and Northern California with the potential to install massive floating wind turbines that could produce 4.6 gigawatts of electricity, enough to power 1.6 million homes.

Interest in offshore wind on the West Coast has grown for years, especially with California's own ambitious goal to cut greenhouse gas emissions. The deep waters off the coast have the potential to produce a significant amount of energy.

But the Defense Department has largely objected to the idea, since the Navy and Air Force use the area for training and testing operations. In response to the growing interest, the Navy released a map in 2017 putting large swaths of California waters off limits.

In 2018, the federal Bureau of Ocean Energy Management solicited interest from wind developers. But negotiations with the Department of Defense have been slow going ever since, effectively blocking wind development off California.

Tuesday's announcement outlines a compromise for a 399-square-mile area off Morro Bay, a site that's appealing to renewable energy companies because of existing transmission lines nearby that once service a retired power plant. It also identifies a location off Humboldt County in Northern California.

"It's our view that the world faces a grave and growing climate crisis," says Dr. Colin Kahl, undersecretary of defense for policy. "Climate change is both a threat to the Department of Defense's operations around the world and an existential challenge to our ability to maintain resilience here at home."

Another key site, just offshore from the Diablo Canyon nuclear power plant, was not included in Tuesday's deal. California's last-remaining nuclear plant is scheduled to completely close by 2025, freeing up more potential transmission lines for offshore wind.

The Biden administration has set a goal of jump-starting the country's offshore wind sector with 30 gigawatts of projects by 2030. Those wind farms will foster tens of thousands of jobs, according to the White House, between renewable energy installers, manufacturers and steelworkers.

"This is a major breakthrough — a major advancement that will allow California to start planning for its carbon-free electricity goals with offshore wind firmly in the picture," says Nancy Rader of the California Wind Energy Association, who also pointed to the challenges. "Offshore wind development off the coast at Morro Bay and Humboldt will require a major port facility in each area to construct the floating platforms and assemble the turbines that will require continued proactive planning by the state and federal governments."

Still, the areas identified in the agreement may not be enough for hitting the administration's clean electricity goal, as well as California's. The state is planning to get 100% of its electricity from zero-emission sources by 2045. To reach that, renewable energy needs to triple statewide with offshore wind playing a key role, reaching 10 GW, according to a recent state analysis. Tuesday's deal could provide just half of that.

A potential lease auction for the offshore wind sites could be held in mid-2022. But the projects will still have to negotiate concerns about the potential impacts on California's fishing industry and shipping channels, as well as any environmental concerns about sensitive ecosystems.

"Far too many questions remain unanswered regarding potential impacts to marine life which is dependent on a healthy ecosystem," says Mike Conroy of the Pacific Coast Federation of Fishermen's Associations. "The fishing industry has been told these areas work best for offshore wind developers; but no one has asked us what areas would work best for us."

This content is from Southern California Public Radio. View the original story at SCPR.org.

Washington State Department of Agriculture entomologist Chris Looney displays a dead Asian giant hornet, a sample sent from Japan and brought in for research last year in Blaine, Wash.; Credit: Elaine Thompson /AFP via Getty Images

Murder hornets. They're back.

Authorities in Washington state have announced that they've confirmed the first U.S. report this year of an Asian giant hornet, or Vespa mandarinia, in a town north of Seattle.

"Basically the only information we have is that a slightly dried out, dead specimen was collected off of a lawn in Marysville," said Sven Spichiger, managing entomologist with the state agriculture department, during a press conference.

"There really isn't even enough information to speculate on how it got there or how long it had been there," Spichiger added.

Because of its withered condition and the fact that male giant hornets don't typically emerge until July, agriculture officials believe the hornet discovered in early June was likely from a previous season and just recently found.

So-called "murder hornets" are native to Asia but have been spotted in Washington state and Canada over the past two years. The sting of the Vespa mandarinia can be life-threatening to humans, and the killer insects are known to wipe out the colonies of their fellow bugs, particularly honey bees.

According to genetic testing of the specimen discovered in Washington this month, the dead hornet was not the same as the other giant hornets discovered in North America since 2019. The hornet's coloration, which indicates it came from southern Asia, also suggested it arrived in "probably a separate event" than the ones previously known, Spichiger said.

But he emphasized that that was not necessarily cause for alarm.

"I want to very much clarify that a single dead specimen does not indicate a population," Spichiger said.

Washington agriculture officials are now setting murder hornet traps in the area of the discovery and are encouraging "citizen scientists" to do the same.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Gloria Majiga-Kamoto, an activist from Malawi, is one of six recipients of the 2021 Goldman Environmental Prize. Majiga-Kamoto has been instrumental in implementing Malawi's ban on thin plastics.; Credit: /Goldman Environmental Prize

For Gloria Majiga-Kamoto, her great awakening to plastic pollution started with goats.

She was working for a local environmental NGO in her native Malawi with a program that gave goats to rural farmers. The farmers would use the goat's dung to produce low-cost, high-quality organic fertilizer.

The problem? The thin plastic bags covering the Malawian countryside.

"We have this very common street food, it's called chiwaya, and it's just really potato fried on the side of the road and it's served in these little blue plastics," Majiga-Kamoto says. "So because it's salty, once the goats get a taste of the salt, they just eat the plastic because they can't really tell that it's inedible. And they die because it blocks the ingestion system — there's no way to survive."

The goats were supposed to reproduce for the program, with the goat kids going on to new farmers. But because of plastic deaths the whole goat chain started falling apart.

"It was a lot of expectation from the farmers waiting to benefit. So you had this farmer who had this one goat and then they lost it. And that means that in that chain of farmers, that's obviously affected quite a number of farmers who won't get their turn."

For Majiga-Kamoto, her experience at the NGO with the plastic-eating goats was the moment it all changed. All of a sudden she started noticing how plastics were everywhere in the Malawian environment and food system — affecting people's livelihoods and health.

The fish in Lake Malawi were eating plastic trash. The country's cows were eating plastic. Researchers found that in one Malawi town 40% of the livestock had plastic in their intestines.

"We're choking in plastics," Majiga-Kamoto says, "And so what it means is that in one way or the other, we as humans are consuming these plastics."

Majiga-Kamoto was also seeing how plastics contributed to the growth of disease. Huge piles of plastic trash were blocking off Malawi's many waterways, creating pungent breeding grounds for mosquitoes that carry malaria and for bacteria that cause cholera.

The 30-year-old says she remembers a time when Malawians didn't rely so much on thin, single-use plastic. "I remember back in the day when we'd go to the market and buy things like fish, like dried fish, you'd get it in newspapers."

But thin plastics have taken off in the last decade or so as new manufacturers sprung up in Malawi, selling products like thin plastic bags at cheap prices that made them affordable and accessible even in the most undeveloped parts of the country. A 2019 UNDP funded report found that Malawi produces an estimated 75,000 tonnes of plastic a year, with 80% reportedly single-use plastic. Single-use plastic refers to bags, straws and bottles that can't be recycled, and thin plastic refers to plastic that's under 60 microns in thickness.

The proliferation of this thin plastic waste led to the Malawian government's 2015 decision to ban the production, distribution and importation of single-use thin plastic. But before the ban could go into full effect, Malawi's plastics manufacturing industry filed an injunction at the country's High Court. The ban stalled.

When Majiga-Kamoto and a group of her fellow environmental NGO-workers and activists heard about the injunction they were angry and frustrated. "It sort of caught our interest to say, 'Wait a minute, you mean that there's actually people in our society who think that this is not a problem and that we should actually continue to live this way?'"

Galvanized, Majiga-Kamoto led a group of local environmental activists and NGOs to actually implement the single-use plastics ban, organizing marches on the judiciary where the decision would be decided. She kept her job at her NGO, the Centre for Environmental Policy and Advocacy, and did this work on her own time.

She rejected the plastic industry's argument that the ban would hurt Malawi's economy — and even debated an industry lobbyist on TV.

Finally in 2019, after multiple injunctions filed by the plastics industry, the High Court ruled in favor of the single-use thin plastic ban. The following year the Malawian government began closing down illegal plastic manufacturers.

Last week Majiga-Kamoto was named one of the six winners of the 2021 Goldman Environmental Prize for her work on this issue. Michael Sutton, executive director of the Goldman Environmental Foundation, says Majiga-Kamoto's fight with the plastic lobby epitomizes the spirit of the prize. "She mustered the troops, the grassroots communities, to take on the government and big industry and won several times," Sutton says, "She not only won the ban in law, but is now holding the government's feet to the fire to enforce it."

And Majiga-Kamoto isn't letting up her pressure to uphold the single-use plastic ban anytime soon. Although she is trying to get some summer vacation time with her family — that is, if she isn't interrupted.

"I was just at the lake a couple of weeks ago and we were there just enjoying the beautiful lake and along come these pieces of plastic." Three plastic bags floated up closer to her, her son and her niece as they played in the water.

Majiga-Kamoto grabbed for the bags.

"My family was laughing to say, 'You shouldn't be working! You're at the lake!' And I'm like, 'But I can't just leave them in there!'"

Julia Simon is a regular contributor to NPR's podcasts and news desks focusing on climate change, energy, and business news.

This content is from Southern California Public Radio. View the original story at SCPR.org.

; Credit: Asa Mathat/TED / Asa Mathat

Part 4 of TED Radio Hour episode An SOS From The Ocean

Legendary oceanographer Sylvia Earle has been exploring and working to protect our oceans for more than half a century. Her message has stayed the same: we're taking our oceans for granted.

About Sylvia Earle

Sylvia Earle is an oceanographer, explorer, and author. She is the president of Mission Blue, an organization that aims to establish marine protected areas around the world. She is also a National Geographic Explorer.

Earle has led more than 50 expeditions and clocked more than 7,000 hours underwater. She was captain of the first all-female team to live underwater in 1970--one of many extended underwater stays. In 1979, she walked untethered on the sea floor at a lower depth than any other woman before or since. In the 1980s, she started the companies Deep Ocean Engineering and Deep Ocean Technologies with engineer Graham Hawkes to design undersea vehicles that allow scientists to work at previously inaccessible depths. In the early 1990s, she served as Chief Scientist of the National Oceanographic and Atmospheric Administration. In 2009, she became the recipient of the million dollar TED Prize to continue her work to protect oceans.

Earle received an associate degree from St. Petersburg Jr. College, has a Bachelor of Science and Master of Science degree from Florida State University, and a Doctorate of Psychology from Duke University.

This segment of TED Radio Hour was produced by Christina Cala and edited by Sanaz Meshkinpour. You can follow us on Twitter @TEDRadioHour and email us at TEDRadio@npr.org.

This content is from Southern California Public Radio. View the original story at SCPR.org.

; Credit: /Courtesy of TED

Part 3 of TED Radio Hour episode: An SOS From The Ocean

In 1998, Alasdair Harris went to Madagascar to research coral reefs. He's worked there ever since. He explains the true meaning of conservation he learned from the island's Indigenous communities.

About Alasdair Harris

Alasdair Harris is a marine biologist and the founder of the organization Blue Ventures. His organization seeks to catalyze and sustain locally-led marine conservation in coastal communities around the world.

His work focuses on rebuilding tropical fisheries and working with coastal people to increase their sources of income.

Harris holds a PhD in tropical marine ecology, and an honorary doctorate of science from the University of Edinburgh.

This segment of TED Radio Hour was produced by Matthew Cloutier and edited by Sanaz Meshkinpour. You can follow us on Twitter @TEDRadioHour and email us at TEDRadio@npr.org.

This content is from Southern California Public Radio. View the original story at SCPR.org.

• Shift deferential of $2 an hour provided for night shift.
• Deputies with advanced degrees will receive extra pay based on highest degree obtained: Associates ($.25 per hour), Bachelors ($.50 per hour), Masters ($.75 per hour).  
• Deputies who possess a Law Enforcement Intermediate Certificate will receive an additional $.25 per hour.
• Deputies who possess a Law Enforcement Advanced Certificate will receive an additional $.50 per hour.  
• A salary increase is given annually upon a successful performance review (dependent upon budget availability).
• Bilingual extra duty pay is provided upon successful completion of testing (dependent upon budget availability).

• Deputies work 12.25 hour shifts, and get a three-day weekend off every other weekend (Fri-Sun), working 14 days out of a 28 day pay period.  
• Applicants must be available to work day and night shifts.  
• Pay is bi-weekly (every 14 days).
• Excellent benefits are offered, including competitive pay, health insurance, dental insurance, and a 5% 401K match.  
• To be considered complete the on line Catawba County application in entirety, including supplemental questions.

• Investigators with advanced degrees will receive extra pay based on highest degree obtained:  Associates ($.25 per hour), Bachelors ($.50 per hour), Masters ($.75 per hour).  
• Investigators who possess a Law Enforcement Intermediate Certificate will receive an additional $.25 per hour.
• Investigators who possess a Law Enforcement Advanced Certificate will receive an additional $.50 per hour.  
• A salary increase is given annually upon a successful performance review (dependent upon budget availability).
• Bilingual extra duty pay is provided upon successful completion of testing (dependent upon budget availability).

• Investigators work 8 hour shifts Monday-Friday. May also be required to work weekends and evening hours.   
• Pay is bi-weekly (every 14 days).
• Excellent benefits are offered, including competitive pay, health insurance, dental insurance, and a 5% 401K match.  
• To be considered complete the on line Catawba County application in entirety, including supplemental questions.

Rescuers search for bodies from the site where a Philippine military C-130 plane crashed in Patikul town, Sulu province, southern Philippines on Sunday, July 4, 2021.; Credit: /Joint Task Force-Sulu via AP

MANILA, Philippines — A Philippine air force C-130 aircraft carrying combat troops crashed in a southern province while landing Sunday, killing at least 29 army soldiers on board and two civilians on the ground, while at least 50 were rescued from the burning wreckage, officials said.

Some soldiers were seen jumping off the aircraft before it crashed and exploded around noon in the periphery of the Jolo airport in Sulu province, military officials said. Two of six villagers who were hit on the ground have died.

Defense Secretary Delfin Lorenzana said rescue and recovery efforts were ongoing. The aircraft had 96 people on board, including three pilots and five crew and the rest were army personnel, the military said, adding 17 soldiers remained unaccounted for by nightfall. The pilots survived but were seriously injured, officials said.

The Lockheed C-130 Hercules was one of two ex-U.S. Air Force aircraft handed over to the Philippines as part of military assistance this year. It crashed while landing shortly before noon Sunday in Bangkal village in the mountainous town of Patikul, military chief of staff Gen. Cirilito Sobejana said.

Military officials said at least 50 people on board were brought to a hospital in Sulu or flown to nearby Zamboanga city and troops were trying to search for the rest. "Per eyewitnesses, a number of soldiers were seen jumping out of the aircraft before it hit the ground, sparing them from the explosion caused by the crash," a military statement said.

Initial pictures released by the military showed the tail section of the cargo plane relatively intact. The other parts of the plane were burned or scattered in pieces in a clearing surrounded by coconut trees. Soldiers and other rescuers with stretchers were seen dashing to and from the smoke-shrouded crash site.

The plane was transporting troops, many of them new soldiers who had just undergone basic training, from the southern Cagayan de Oro city for deployment in Sulu, officials said.

"They were supposed to join us in our fight against terrorism," Sulu military commander Maj. Gen. William Gonzales said. Government forces have been battling Abu Sayyaf militants in the predominantly Muslim province of Sulu for decades.

It was not immediately clear what caused the crash. Regional military commander Lt. Gen. Corleto Vinluan said it was unlikely that the aircraft took hostile fire, and cited witnesses as saying that it appeared to have overshot the runway then crashed in the periphery of the airport.

"It's very unfortunate," Sobejana told reporters. "The plane missed the runway and it was trying to regain power but failed and crashed."

An air force official told The Associated Press that the Jolo runway is shorter than most others in the country, making it more difficult for pilots to adjust if an aircraft misses the landing spot. The official, who has flown military aircraft to and from Jolo several times, spoke on condition of anonymity because of a lack of authority to speak publicly.

Initial pictures showed that the weather was apparently fine in Sulu although other parts of the Philippines were experiencing rains due to an approaching tropical depression. The airport in Sulu's main town of Jolo is located a few kilometers (miles) from a mountainous area where troops have battled Abu Sayyaf militants. Some militants have aligned themselves with the Islamic State group.

The U.S. and the Philippines have separately blacklisted Abu Sayyaf as a terrorist organization for bombings, ransom kidnappings and beheadings. It has been considerably weakened by years of government offensives but remains a threat.

President Rodrigo Duterte expanded the military presence in Sulu into a full division in late 2018, deploying hundreds of additional troops, air force aircraft and other combat equipment after vowing to wipe out the Abu Sayyaf and allied foreign and local gunmen.

Government forces at the time were running after Muslim armed groups a year after quelling the five-month siege of southern Marawi city by hundreds of militants linked to the Islamic State group. More than 1,000 people, mostly militants and long-elusive Abu Sayyaf commanders, were killed in months of intense air and ground assaults.

Sunday's crash comes as the limited number of military aircraft has been further strained, as the air force helped transport medical supplies, vaccines and protective equipment to far-flung island provinces amid spikes in COVID-19 infections.

The Philippine government has struggled for years to modernize its military, one of Asia's least equipped, as it dealt with decades-long Muslim and communist insurgencies and territorial rifts with China and other claimant countries in the South China Sea.

This content is from Southern California Public Radio. View the original story at SCPR.org.

SURFSIDE, Fla. — Crews used explosives late Sunday night to demolish the remaining structure at Champlain Towers South in Surfside, Fla.

The heavily damaged condo building was knocked down at about 10:30 p.m. Eastern time.

The targeted blast caused the tower to fold and crumble, sending a large plume of dust and debris over a section of the beachside community. A crowd watching from a distance prayed as the building came down.

Before the structure was leveled, Miami-Dade County police urged residents who live nearby to remain indoors and shelter in place.

Miami-Dade County officials said removing the tower was an essential step so search and rescue teams could resume scouring the rubble pile for victims of the disaster.

Officials suspended recovery efforts on Saturday because of concerns about the danger posed by the unstable building.

"It will be safe to resume the search activities very shortly after the blast and that's when we'll resume it," said Miami-Dade County Mayor Daniella Levine Cava at a press conference Sunday evening.

Demolition of the tower was also accelerated because of Tropical Storm Elsa, which could hit South Florida with high winds and heavy rains as early as Monday.

Search efforts had been ongoing since the morning of June 24, when much of the 12-story condo complex suffered a "progressive collapse" and dozens of apartments were reduced to rubble in a matter of seconds.

The number of confirmed dead from the disaster remains at 24, with the number of people unaccounted for at 121.

Rep. Debbie Wasserman Schultz, D-Fla., told reporters Sunday the demolition of the remaining tower added to the sorrow for families who lived in the complex, destroying homes and possessions.

"So often demolitions of buildings are a spectacle, it's almost like a show," Schultz said. "This demolition is a tragic situation."

Local officials assured former residents and the public that everything possible had been done to rescue pets left behind in the structure.

"Folks can be comfortable we're not leaving anyone behind, including our beloved pets," Surfside Mayor Charles Burkett told reporters.

Multiple investigations are already underway into the cause of the collapse.

Documents acquired by NPR from an anonymous source show the condo association's board received warnings from an engineering firm beginning in 2018 that the structure needed extensive repairs.

A memo sent by the association to Champlain Towers South residents ahead of a May 2021 board meeting acknowledged the "desperate needs of the building."

This content is from Southern California Public Radio. View the original story at SCPR.org.

A tropical storm with 65-mile-an-hour winds is drenching Cuba, and is expected to reach Key West and the west coast of Florida within the next 48 hours.

The National Hurricane Center expects Tropical Storm Elsa to drop between 5 and 10 inches of rain on central and western Cuba, leading to significant flooding and mudslides. The storm probably will weaken somewhat as it crosses the island, but could strengthen again as it approaches Florida.

According to the Associated Press, Cuban officials evacuated 180,000 people as a precaution against the possibility of heavy flooding.

Most of those evacuated stayed at relatives' homes, others went to government shelters, and hundreds living in mountainous areas took refuge in caves prepared for emergencies. The storm had killed at least three people on other Caribbean islands before it reached Cuba

The National Weather Service says that the western coast of Florida, including Tampa Bay, can expect a storm surge that would lift water levels between two and four feet. Much of Florida could see heavy rainfall that could reach six inches in some places. The storm will then bring heavy rains to Georgia and the Carolinas later in the week.

Florida officials were worried that the storm could destabilize what was left of the condominium building that partially collapsed over a week ago. In order to avoid an uncontrolled collapse, they approved the demolition of the remaining portion of the building, which took place on Sunday night.

"The hurricane was coming, the potential for that building to fall on the pile with the victims in it was a tragic thought," Surfside Mayor Charles Burkett told NPR on Monday.

It's early in the hurricane season. The National Oceanic and Atmospheric Administration has predicted a busier-than-average Atlantic hurricane season, but it would be hard to top last year's, which set an all-time record with 30 named storms.

Tropical storms are fueled by warm water in the upper layers of the ocean, and ocean temperatures have been rising as heat is trapped by greenhouse gases.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Bill Cosby gestures outside his home in Elkins Park, Pa., on June 30, 2021, after being released from prison when the Pennsylvania's supreme court overturned his sexual assault conviction. Cosby expressed support for former TV co-star Phylicia Rashad's freedom of speech after she defended him in a tweet.; Credit: Matt Rourke/AP

Bill Cosby called on Howard University to support former co-star Phylicia Rashad's freedom of speech after she expressed support for him when his sexual assault conviction was overturned.

In a statement, Cosby also lashed out at the media, comparing journalists to the rioters who stormed the Capitol in January.

"Howard University you must support ones Freedom of Speech (Ms. Rashad), which is taught or suppose to be taught everyday at that renowned law school, which resides on your campus," Cosby said in a statement provided to NPR by his spokesman Andrew Wyatt.

"This mainstream media has become the Insurrectionists, who stormed the Capitol," Cosby continued in his statement. "Those same Media Insurrectionists are trying to demolish the Constitution of these United State of America on this Independence Day."

Cosby concluded by saying, "WE THE PEOPLE STAND IN SUPPORT OF MS. PHYLICIA RASHAD" in all caps.

Cosby's support of Rashad comes after the actress, who played his TV wife in The Cosby Show, defended the comedian in a tweet. Cosby was released from prison last week when the Pennsylvania Supreme Court vacated his sexual assault conviction on the grounds that his due process rights were violated.

"FINALLY!!!! A terrible wrong is being righted- a miscarriage of justice is corrected!" Rashad said last week.

The tweet has since been removed and Rashad later backpedaled, writing that she "fully support survivors of sexual assault coming forward." She also sent a letter of apology to Howard students

Many Howard alumni had expressed disappointment at the remarks. Howard University responded with its own tweet, stating that Dean Rashad's "initial tweet lacked sensitivity towards survivors of sexual assault."

Rashad was recently named Dean of Howard University's Chadwick Boseman College of Fine Arts.

Rashad, an acclaimed stage and screen artist, graduated from Howard magna cum laude in 1970 with a bachelor's in fine arts. She returned as a guest lecturer and adjunct faculty member.

In a statement announcing her appointment in May, Provost Anthony K. Wutoh said Rashad's "passion for the arts and student success makes her a perfect fit for this role."

One of the students Rashad mentored at Howard was the late actor Chadwick Boseman, for whom the school's College of Fine Arts is named.

This content is from Southern California Public Radio. View the original story at SCPR.org.

The Akshaya Patra Foundation reduced the process time taken from planning the menu to delivery to schools by using mobility solution and automation.

Panelists in a discussion on ‘Mobility Megatrends 2050’, highlighted that in the next decade, with electrification, autonomous driving, smart and connected infrastructure, modal diversity, and mobility that is integrated, resilient, shared, and sustainable – powered by disruptive business models, will transform and shape up of the automotive industry. The industry is racing towards a new world, driven by sustainability and changing consumer behaviour, encompassing electric vehicles, autonomous cars, mobility fleet sharing, and always connected.

“The technology services industry, at some level, is recession proof,” Premji said at the company’s 76th annual general meeting on Tuesday. “In good times, clients spend on new initiatives and business transformation and serving customers digitally. They focus on reducing costs when times are not so good,” he said addressing a question on inflation concerns.

With the advent of disruptive technologies such as artificial intelligence, blockchain, and data analytics, banks across the world are embracing a new era of innovation to enhance their services and improve customer experiences. These innovations are empowering banks to provide personalized, efficient, reliable, and secure financial solutions to their customers.

The Catawba County Sheriff�s Office, in conjunction with The Cognitive Connection and The Foothills Coalition, is sponsoring an Operation Pill Stoppers program that now provides fixed locations for citizens to properly dispose of their unused and unwanted medications.

�Catawba Communities,� a monthly show which will feature information about programs and services provided by local governments, school systems and associated agencies across Catawba County, will premiere on Charter Communications� Government Channel (Channel 3) on Tuesday, August 23, 2011, at 8:00 p.m.

A delegation of high school students representing the Catawba County Youth Council and 4-H attended NC Citizenship Focus, which was held in Raleigh, where more than 200 youth and adults representing over 75 counties exchanged ideas, gained knowledge and learned through hands on experiences about the different levels and branches of government.

The information was developed and compiled by the Children's Agenda Planning Committee, appointed by the Catawba County Board of Commissioners. The committee's vision is to ensure a safe community where all children are engaged, enriched and equipped to reach their full potential.

Architectural plans have been finalized for the new Sherrills Ford branch of Catawba County Library. The 10,000 square foot facility, to be erected on 2.5 acres near the intersection of Highway 150 and Sherrills Ford Road, is expected to be completed in 2014.